GlassScriptPhysician profile
Sarah E Maltba
NPI 1821670878
$3,129.01
in general payments reported to CMS, 2019-2025
27 companies · $104 in 2025
The $104 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $417 · 2022: $1,598 · 2023: $873 · 2024: $137 · 2025: $104.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,113.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,113.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $910.96 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Glaxosmithkline, LLC. | $394.08 | 2021-2024 | Trelegy Ellipta |
| Astrazeneca Pharmaceuticals LP | $350.65 | 2021-2024 | Farxiga, Breztri, Airsupra |
| Lilly USA, LLC | $180.11 | 2021-2024 | Mounjaro, Zepbound, Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $164.12 | 2022-2023 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $158.22 | 2022-2023 | Xifaxan, Relistor |
| Boehringer Ingelheim Pharmaceuticals, INC. | $136.92 | 2021-2023 | Jardiance |
| Amgen INC. | $96.83 | 2021-2022 | |
| Pfizer INC. | $95.88 | 2021-2023 | |
| Medtronic, INC. | $83.62 | 2022-2024 | Intellis Adaptivestim |
| Exact Sciences Corporation | $81.16 | 2023-2024 | Cologuard Collection Kit |
| Scilex Pharmaceuticals INC. | $74.17 | 2022-2023 | Ztlido |
| Sanofi-Aventis U.S. LLC | $58.93 | 2022-2023 | |
| Sumitomo Pharma America, INC. | $44.43 | 2023-2025 | Gemtesa |
| Amarin Pharma, INC. | $43.51 | 2021-2022 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $39.94 | 2022-2023 | Verquvo |
| Abbvie INC. | $29.97 | 2024-2025 | |
| Janssen Pharmaceuticals, INC | $29.20 | 2022 | |
| Ironwood Pharmaceuticals, INC | $22.15 | 2023 | Linzess |
| Mylan Specialty L.P. | $21.59 | 2022 | |
| Viatris Specialty LLC | $19.06 | 2025 | Yupelri |
| Insulet Corporation | $18.89 | 2021 | |
| Hikma Pharmaceuticals USA | $17.59 | 2022 | |
| Ultragenyx Pharmaceutical INC. | $16.56 | 2022 | |
| Nevro Corp. | $13.88 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $13.75 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $12.84 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sarah Maltba listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.